eli lilly retatrutide phase iii results

How much weight did adults lose in the TRIUMPH-2 retatrutide Phase III trial?

The main weight-loss result reported from TRIUMPH-2 was substantial, but it applies specifically to the highest tested dose in that trial.

The reported average weight loss

Adults who received the highest tested dose of retatrutide lost nearly one-fifth of their starting weight on average.

That result came from the Phase III TRIUMPH-2 trial, which studied retatrutide in adults with overweight or obesity and type 2 diabetes.

What the trial included

TRIUMPH-2 lasted 80 weeks and included 1,152 adults. Participants received either retatrutide or placebo injections, along with counseling on diet and physical activity.

The reports also said blood sugar control improved in the retatrutide group, while nausea and diarrhea were more common.

What to keep in mind

Retatrutide is described in the reports as experimental. Eli Lilly sponsored the study, and the findings were published in *The Lancet*. For medical decisions or current availability, readers should check the latest official information from regulators, the company, or a clinician.

Who was studied in the TRIUMPH-2 retatrutide trial?

TRIUMPH-2 was not a general weight-loss study of all adults. The reported trial population was more specific.

Who was included

The trial studied 1,152 adults with overweight or obesity and type 2 diabetes.

That matters because the results are most directly relevant to people matching that study group, not necessarily to people without type 2 diabetes or outside the trial’s adult population.

What participants received

Participants were assigned to receive retatrutide or placebo injections. The reports also say they received counseling on diet and physical activity during the 80-week trial.

Retatrutide itself is described as an experimental once-weekly injection. It is also described as a triple receptor agonist because it activates three hormone receptors.

Why the participant group matters

When reading the results, keep the study group in mind. The reported weight-loss and blood-sugar findings came from adults with overweight or obesity and type 2 diabetes, in a sponsored Phase III trial.

For broader eligibility or availability, the available reports do not provide enough detail. Check current official announcements or medical guidance before assuming who could use it.

What side effects were more common with retatrutide in TRIUMPH-2?

The TRIUMPH-2 reports named two side effects that were more common with retatrutide.

The side effects reported

Nausea and diarrhea were reported as more common among participants receiving retatrutide.

The available context does not give rates, severity levels, or how long those symptoms lasted. It only confirms that these side effects were more common in the trial reporting.

What else the trial found

TRIUMPH-2 studied retatrutide as an experimental once-weekly injection for adults with overweight or obesity and type 2 diabetes. Participants received retatrutide or placebo injections, along with diet and physical activity counseling.

The reports said adults at the highest tested dose lost nearly one-fifth of their starting weight on average, and blood sugar control improved.

What readers should not assume

The available reports do not confirm whether retatrutide is appropriate for any individual person, or how side effects would be managed in regular care. Because this is medical information about an experimental drug, the safest next step is to check current official medical information and talk with a qualified clinician.

How was retatrutide used in the Phase III TRIUMPH-2 trial?

In TRIUMPH-2, retatrutide was studied as an injection, not as a pill.

How retatrutide was given

Retatrutide was described as an experimental once-weekly injection.

In the Phase III TRIUMPH-2 trial, participants received retatrutide or placebo injections. The study also included counseling on diet and physical activity.

Who received it in the trial

The trial included 1,152 adults with overweight or obesity and type 2 diabetes. It lasted 80 weeks.

The reports do not provide a full dosing schedule in the available context beyond noting that retatrutide was given once weekly and that the highest tested dose was tied to the largest reported average weight loss.

What was measured

The reports highlighted weight loss and blood sugar control. At the highest tested dose, adults lost nearly one-fifth of their starting weight on average, and blood sugar control improved.

Nausea and diarrhea were also reported as more common. Since retatrutide is still described as experimental in the reports, readers should look for the latest official information before drawing conclusions about real-world use.

Tag: eli lilly retatrutide phase iii results